🔎 Trials Near Me

Home › Burkitt Lymphoma › Illinois › Chicago

Burkitt Lymphoma clinical trials in Chicago, IL

14 studies for Burkitt Lymphoma are looking for participants at sites in and around Chicago (within about 30 miles). Open a study to see who can join and how to contact the study team.

Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

RecruitingPhase 2
  • Lurie Children's Hospital-Chicago, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
366 Days – 46 Years · All sexes · Updated Oct 2, 2026 · NCT06124157

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

RecruitingPhase 3
  • Northwestern University, Chicago
  • Rush MD Anderson Cancer Center, Chicago
  • University of Illinois, Chicago
  • and 1 more
Ages 18 to 39 · All sexes · Updated Oct 2, 2026 · NCT03150693

Blinatumomab Consolidation in Real World

RecruitingObservational studyHealthy volunteers welcome
  • Northwestern University, Chicago
  • The University of Chicago, Chicago
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07117136

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

RecruitingPhase 2
  • Northwestern University, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT03739814

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

RecruitingPhase 2
  • Lurie Children's Hospital-Chicago, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
365 Days · All sexes · Updated Sep 25, 2026 · NCT06317662

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

RecruitingPhase 2
  • Lurie Children's Hospital-Chicago, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
Ages 1 to 30 · All sexes · Updated Sep 1, 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

RecruitingPhase 3
  • Lurie Children's Hospital-Chicago, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
365 Days – 25 Years · All sexes · Updated Aug 25, 2026 · NCT03959085

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

RecruitingPhase 2
  • Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Ages 7 to 25 · All sexes · Updated Aug 19, 2026 · NCT05082519

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

RecruitingPhase 1/2
  • Research Site, Chicago
Ages 12 and older · All sexes · Updated Aug 19, 2026 · NCT06137118

Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

RecruitingPhase 1/2
  • Research Site, Chicago
Ages 12 and older · All sexes · Updated Jul 13, 2026 · NCT07109219

Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

RecruitingPhase 2
  • University of Chicago Comprehensive Cancer Center, Chicago
Ages 18 to 54 · All sexes · Updated Mar 17, 2026 · NCT06918431

ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML

RecruitingPhase 1
  • University of Chicago Comprehensive Cancer Center, Chicago
Ages 18 and older · All sexes · Updated Nov 4, 2025 · NCT03595917

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

RecruitingPhase 1/2
  • University of Chicago, Chicago
Ages 15 to 50 · All sexes · Updated Sep 9, 2025 · NCT04150497

Study of Nutrition and Exercise in Adults Hospitalized for Treatment of Acute Lymphoblastic Leukemia (ALL)

Recruiting
  • University of Chicago Medicine Comprehensive Cancer Center, Chicago
Ages 18 to 50 · All sexes · Updated Jun 19, 2025 · NCT06785324

Burkitt Lymphoma trials in other cities

Other studies in Chicago

From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.